• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4618546)   Today's Articles (6444)   Subscriber (49402)
For: LoCoco S, Covens A, Carney M, Franssen E, Dogde R, Rosen B, Osborne R, Kerr I, Buckman R, Soper J. Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian-American comparative study. Gynecol Oncol 1995;59:194-9. [PMID: 7590472 DOI: 10.1006/gyno.1995.0007] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Number Cited by Other Article(s)
1
Warren JL, Barbera L, Bremner KE, Yabroff KR, Hoch JS, Barrett MJ, Luo J, Krahn MD. End-of-life care for lung cancer patients in the United States and Ontario. J Natl Cancer Inst 2011;103:853-62. [PMID: 21593012 DOI: 10.1093/jnci/djr145] [Citation(s) in RCA: 78] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]  Open
2
von Gruenigen V, Daly B, Gibbons H, Hutchins J, Green A. Indicators of survival duration in ovarian cancer and implications for aggressiveness of care. Cancer 2008;112:2221-7. [PMID: 18348300 DOI: 10.1002/cncr.23391] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
3
Scarfone G, Bolis G. Multimodal approach to ovarian cancer. Ann Oncol 2006;17 Suppl 5:v199-200. [PMID: 16807456 DOI: 10.1093/annonc/mdj981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
4
Martínez-Saíd H, Rincón DG, Montes de Oca MM, Ruiz GC, Ponce JLA, López-Graniel CM. Predictive factors for irresectability in advanced ovarian cancer. Int J Gynecol Cancer 2004;14:423-30. [PMID: 15228414 DOI: 10.1111/j.1048-891x.2004.014301.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]  Open
5
Berchuck A, Iversen ES, Lancaster JM, Dressman HK, West M, Nevins JR, Marks JR. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 2004;190:910-25. [PMID: 15118612 DOI: 10.1016/j.ajog.2004.02.005] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
6
Baekelandt M. The potential role of neoadjuvant chemotherapy in advanced ovarian cancer. Int J Gynecol Cancer 2003;13 Suppl 2:163-8. [PMID: 14656274 DOI: 10.1111/j.1525-1438.2003.13354.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]  Open
7
von Gruenigen VE, Frasure HE, Reidy AM, Gil KM. Clinical disease course during the last year in ovarian cancer. Gynecol Oncol 2003;90:619-24. [PMID: 13678735 DOI: 10.1016/s0090-8258(03)00418-9] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
8
Donovan KA, Greene PG, Shuster JL, Partridge EE, Tucker DC. Treatment preferences in recurrent ovarian cancer. Gynecol Oncol 2002;86:200-11. [PMID: 12144829 DOI: 10.1006/gyno.2002.6748] [Citation(s) in RCA: 80] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
9
Selman AE, Copeland LJ. Secondary cytoreductive surgery in the patient with recurrent ovarian cancer is often beneficial. Crit Rev Oncol Hematol 2002;41:335-41. [PMID: 11880209 DOI: 10.1016/s1040-8428(01)00174-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]  Open
10
Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 2000;78:269-74. [PMID: 10985879 DOI: 10.1006/gyno.2000.5926] [Citation(s) in RCA: 128] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
11
Dauplat J, Le Bouëdec G, Pomel C, Scherer C. Cytoreductive surgery for advanced stages of ovarian cancer. SEMINARS IN SURGICAL ONCOLOGY 2000;19:42-8. [PMID: 10883023 DOI: 10.1002/1098-2388(200007/08)19:1<42::aid-ssu7>3.0.co;2-m] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA